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Background: Coronary heart disease (CHD) is the leading cause of death in women in the United States, and lipid-lowering therapy can reduce 
CHD events in women. Previous studies have shown that women are less likely to achieve optimal low-density lipoprotein (LDL) levels compared to 
men. We hypothesized that this was due to differences in their lipid lowering medications.
Methods: We conducted a retrospective analysis of outpatient electronic health records (EHR) from a large cardiology practice from September 
2008 to September 2009. The most recent lipid profile and lipid lowering medications and doses were extracted from the EHR. Statin potency was 
assessed based on the brand and dose of statin.
Results: We identified 9,950 CHD patients of which 3366 (34%) were women. Compared to men, women were older (mean age 73 vs. 69, p < 
0.001), had more hypertension (74% vs. 63%, p < 0.0001), but had similar rates of diabetes (27% vs. 27%, p = 0.8), smoking (9% vs. 9%, p =0.7), 
and obesity (47% vs. 47%, p = 0.8). Fewer women achieved an LDL goal < 70 mg/dL (31% vs. 38%, p < 0.0001) compared to men. Both younger (< 
65 years) and older (> 65 years) CHD women were less likely to achieve an LDL < 70 mg/dL (27% vs. 33%, p = 0.002 and 32% vs. 41%, p < 0.0001 
respectively) compared to similarly aged men. Compared to men, more women were not taking a statin (17% vs. 12%, p < 0.0001). Among women 
on statin therapy alone, fewer women compared to men were on a high potency statin (25% vs. 31%, p < 0.0001) and fewer women compared to 
men were on combination therapy with a statin plus another lipid lowering medication (22% vs. 30%, p < 0.0001).
Conclusions: In clinical practice both younger and older CHD women are less likely to achieve optimal LDL levels compared to men, despite 
women being more high risk. This may be because women are less aggressively treated with lipid-lowering medications than men. There exists a need 
for further study and gender specific interventions to improve lipid goal attainment in CHD women.
